Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: Tailoring better vaccination strategies

M. Manuela Rosado, Francesco Gesualdo, Valentina Marcellini, Antonio Di Sabatino, Gino Roberto Corazza, Maria Paola Smacchia, Bruno Nobili, Carlo Baronci, Lidia Russo, Francesca Rossi, Rita De Vito, Luciana Nicolosi, Alessandro Inserra, Franco Locatelli, Alberto E. Tozzi, Rita Carsetti

Research output: Contribution to journalArticle

Abstract

Splenectomized patients are exposed to an increased risk of septicemia caused by encapsulated bacteria. Defense against infection is ensured by preformed serum antibodies produced by long-lived plasma cells and by memory B cells that secrete immunoglobulin in response to specific antigenic stimuli. Studying a group of asplenic individuals (57 adults and 21 children) without additional immunologic defects, we found that spleen removal does not alter serum anti-pneumococcal polysaccharide (PnPS) IgG concentration, but reduces the number of PnPS-specific memory B cells, of both IgM and IgG isotypes. The number of specific memory B cells was low in splenectomized adults and children that had received the PnPS vaccine either before or after splenectomy. Seven children were given the 13-valent pneumococcal conjugated vaccine after splenectomy. In this group, the number of PnPS-specific IgG memory B cells was similar to that of eusplenic children, suggesting that pneumococcal conjugated vaccine administered after splenectomy is able to restore the pool of anti-PnPS IgG memory B cells. Our data further elucidate the crucial role of the spleen in the immunological response to infections caused by encapsulated bacteria and suggest that glycoconjugated vaccines may be the most suitable choice to generate IgG-mediated protection in these patients.

Original languageEnglish
Pages (from-to)2659-2670
Number of pages12
JournalEuropean Journal of Immunology
Volume43
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Memory Disorders
Tetanus
Splenectomy
Streptococcus pneumoniae
Vaccination
B-Lymphocytes
Immunoglobulin G
Polysaccharides
Antibodies
Pneumococcal Vaccines
Spleen
Bacteria
Infection
Plasma Cells
Serum
Immunoglobulin M
Immunoglobulins
Sepsis
Vaccines

Keywords

  • Asplenia
  • Memory B cells
  • Serum anti-PnPS
  • Splenectomy
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

@article{cd189506f80b4d54bbb0f1713f8242f0,
title = "Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: Tailoring better vaccination strategies",
abstract = "Splenectomized patients are exposed to an increased risk of septicemia caused by encapsulated bacteria. Defense against infection is ensured by preformed serum antibodies produced by long-lived plasma cells and by memory B cells that secrete immunoglobulin in response to specific antigenic stimuli. Studying a group of asplenic individuals (57 adults and 21 children) without additional immunologic defects, we found that spleen removal does not alter serum anti-pneumococcal polysaccharide (PnPS) IgG concentration, but reduces the number of PnPS-specific memory B cells, of both IgM and IgG isotypes. The number of specific memory B cells was low in splenectomized adults and children that had received the PnPS vaccine either before or after splenectomy. Seven children were given the 13-valent pneumococcal conjugated vaccine after splenectomy. In this group, the number of PnPS-specific IgG memory B cells was similar to that of eusplenic children, suggesting that pneumococcal conjugated vaccine administered after splenectomy is able to restore the pool of anti-PnPS IgG memory B cells. Our data further elucidate the crucial role of the spleen in the immunological response to infections caused by encapsulated bacteria and suggest that glycoconjugated vaccines may be the most suitable choice to generate IgG-mediated protection in these patients.",
keywords = "Asplenia, Memory B cells, Serum anti-PnPS, Splenectomy, Streptococcus pneumoniae",
author = "Rosado, {M. Manuela} and Francesco Gesualdo and Valentina Marcellini and {Di Sabatino}, Antonio and Corazza, {Gino Roberto} and Smacchia, {Maria Paola} and Bruno Nobili and Carlo Baronci and Lidia Russo and Francesca Rossi and Vito, {Rita De} and Luciana Nicolosi and Alessandro Inserra and Franco Locatelli and Tozzi, {Alberto E.} and Rita Carsetti",
year = "2013",
month = "10",
doi = "10.1002/eji.201343577",
language = "English",
volume = "43",
pages = "2659--2670",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "wiley",
number = "10",

}

TY - JOUR

T1 - Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy

T2 - Tailoring better vaccination strategies

AU - Rosado, M. Manuela

AU - Gesualdo, Francesco

AU - Marcellini, Valentina

AU - Di Sabatino, Antonio

AU - Corazza, Gino Roberto

AU - Smacchia, Maria Paola

AU - Nobili, Bruno

AU - Baronci, Carlo

AU - Russo, Lidia

AU - Rossi, Francesca

AU - Vito, Rita De

AU - Nicolosi, Luciana

AU - Inserra, Alessandro

AU - Locatelli, Franco

AU - Tozzi, Alberto E.

AU - Carsetti, Rita

PY - 2013/10

Y1 - 2013/10

N2 - Splenectomized patients are exposed to an increased risk of septicemia caused by encapsulated bacteria. Defense against infection is ensured by preformed serum antibodies produced by long-lived plasma cells and by memory B cells that secrete immunoglobulin in response to specific antigenic stimuli. Studying a group of asplenic individuals (57 adults and 21 children) without additional immunologic defects, we found that spleen removal does not alter serum anti-pneumococcal polysaccharide (PnPS) IgG concentration, but reduces the number of PnPS-specific memory B cells, of both IgM and IgG isotypes. The number of specific memory B cells was low in splenectomized adults and children that had received the PnPS vaccine either before or after splenectomy. Seven children were given the 13-valent pneumococcal conjugated vaccine after splenectomy. In this group, the number of PnPS-specific IgG memory B cells was similar to that of eusplenic children, suggesting that pneumococcal conjugated vaccine administered after splenectomy is able to restore the pool of anti-PnPS IgG memory B cells. Our data further elucidate the crucial role of the spleen in the immunological response to infections caused by encapsulated bacteria and suggest that glycoconjugated vaccines may be the most suitable choice to generate IgG-mediated protection in these patients.

AB - Splenectomized patients are exposed to an increased risk of septicemia caused by encapsulated bacteria. Defense against infection is ensured by preformed serum antibodies produced by long-lived plasma cells and by memory B cells that secrete immunoglobulin in response to specific antigenic stimuli. Studying a group of asplenic individuals (57 adults and 21 children) without additional immunologic defects, we found that spleen removal does not alter serum anti-pneumococcal polysaccharide (PnPS) IgG concentration, but reduces the number of PnPS-specific memory B cells, of both IgM and IgG isotypes. The number of specific memory B cells was low in splenectomized adults and children that had received the PnPS vaccine either before or after splenectomy. Seven children were given the 13-valent pneumococcal conjugated vaccine after splenectomy. In this group, the number of PnPS-specific IgG memory B cells was similar to that of eusplenic children, suggesting that pneumococcal conjugated vaccine administered after splenectomy is able to restore the pool of anti-PnPS IgG memory B cells. Our data further elucidate the crucial role of the spleen in the immunological response to infections caused by encapsulated bacteria and suggest that glycoconjugated vaccines may be the most suitable choice to generate IgG-mediated protection in these patients.

KW - Asplenia

KW - Memory B cells

KW - Serum anti-PnPS

KW - Splenectomy

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=84885733691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885733691&partnerID=8YFLogxK

U2 - 10.1002/eji.201343577

DO - 10.1002/eji.201343577

M3 - Article

C2 - 23813052

AN - SCOPUS:84885733691

VL - 43

SP - 2659

EP - 2670

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 10

ER -